Astellas agrees a deal for the ex-US rights of Frequency’s lead drug candidate, FX-322, after the latter company posted positive results in a Phase I/II trial.
The share price of BMS sank by over 7% after it stated that it would need to divest Celgene’s Otezla, a blockbuster treatment for psoriasis and psoriatic arthritis.
Lonza expands its HPAPI production capacity at its Switzerland facility after entering an agreement with AstraZeneca, and invests in manufacturing to establish efficiency.
Aptar Group acquires two pharmaceutical services companies, Nanopharm and Gateway Analytical, to boost its analytical, testing, and development capabilities.
Lonza announces that its Specialty Ingredients business will operate independently by ‘mid-2020’ and will cut away approximately 130 roles at the same time.
Mallinckrodt states that its specialty branded portfolio will be named Sonorant Therapeutics and, in a U-turn, this side of the business will take Amitiza with it.
